Oxigene Reports Positive Data For Zybrestat In Platinum-Resistant Ovarian Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Novel vascular disrupting agent is also in studies for anaplastic thyroid cancer and macular degeneration.